alendronate has been researched along with methotrexate in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Gündüz, OH; Ozoran, K; Uçan, H; Yilmaz, L; Yücel, M | 1 |
| Ambler, GR; Chaitow, J; McDonald, DW; Ouvrier, RA; Rogers, M | 1 |
| Clemente, DA; Damron, TA; Horton, JA; Margulies, BS; Murray, GM; Spadaro, JA; Strauss, JA | 1 |
| Kaneko, F; Nakamura, K; Oyama, N; Satoh, M; Yamada, H | 1 |
| Bargagli, E; Bertelli, P; Gonnelli, S; Olivieri, C; Penza, F; Rottoli, P; Volterrani, L | 1 |
| Fett, N; Liu, RH | 1 |
| Tu, J; Von Nida, J | 1 |
| Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M | 1 |
| Krause, ML; Lehman, JS; Warrington, KJ | 1 |
| Adams, L; Alsalleeh, F; Bavitz, B; Keippel, J | 1 |
| Kang, YS; Lee, NY | 1 |
| Chu, W; Cui, S; Huang, Y; Liao, Y; Yan, M; Yang, C; Zhang, X; Zhao, C | 1 |
| Chen, S; Fan, S; Liu, G; Qin, A; Sun, X; Tang, P; Xie, Z; Zhang, J; Zhu, P | 1 |
| Gao, C; Wang, M; Yan, C; Zhu, P | 1 |
3 review(s) available for alendronate and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Rare localizations of bone sarcoidosis: two case reports and review of the literature.
Topics: Alendronate; Bone Diseases; Bone Neoplasms; Diagnosis, Differential; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Methotrexate; Methylprednisolone; Middle Aged; Osteolysis; Radiography; Rare Diseases; Ribs; Sarcoidosis; Skull; Spine; Treatment Outcome | 2011 |
Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought.
Topics: Alendronate; Antineoplastic Protocols; Arthritis; Breast Neoplasms; Combined Modality Therapy; Dermatologic Agents; Dermatomyositis; Diagnosis, Differential; Drug Therapy, Combination; Female; Histiocytosis; Humans; Lymphatic Metastasis; Mediastinal Neoplasms; Methotrexate; Middle Aged; Prednisone | 2011 |
2 trial(s) available for alendronate and methotrexate
| Article | Year |
|---|---|
Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Calcium; Clinical Chemistry Tests; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Methotrexate; Middle Aged; Osteoporosis, Postmenopausal; Prednisolone; Treatment Outcome | 2001 |
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Topics: Adult; Aged; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; Betamethasone; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Cyclosporine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Injections, Intra-Articular; Lumbar Vertebrae; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome; Young Adult | 2014 |
13 other study(ies) available for alendronate and methotrexate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.
Topics: Alendronate; Calcinosis; Child; Dermatomyositis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Methotrexate; Prednisone; Radiography; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Male; Methotrexate; Rats; Rats, Sprague-Dawley | 2006 |
Treatment trial of multicentric reticulohistiocytosis with a combination of predonisolone, methotrexate and alendronate.
Topics: Adult; Alendronate; Anti-Inflammatory Agents; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Methotrexate; Prednisolone | 2008 |
Metastatic malignant melanoma and dermatomyositis: A paraneoplastic phenomenon.
Topics: Adult; Alendronate; Antibodies, Antinuclear; Calcium; Dermatologic Agents; Dermatomyositis; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Melanoma; Methotrexate; Paraneoplastic Syndromes; Positron-Emission Tomography; Prednisolone; Skin Neoplasms; Treatment Outcome; Vitamin D | 2011 |
Multicentric reticulohistiocytosis can mimic rheumatoid arthritis.
Topics: Alendronate; Arthritis, Rheumatoid; Biopsy, Needle; Diagnosis, Differential; Drug Therapy, Combination; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Hydroxychloroquine; Immunohistochemistry; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome | 2014 |
Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report.
Topics: Aged; Alendronate; Amoxicillin; Anti-Bacterial Agents; Apicoectomy; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Drug Interactions; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Methotrexate; Osteoporosis; Tooth Extraction; Wound Healing | 2014 |
The Changes by Hypoxia Inducible Factor-1alpha (HIF-1α) on Taurine Uptake in Brain Capillary Endothelial Cells at High Glucose Conditions.
Topics: Alendronate; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Glucose; Hypoxia-Inducible Factor 1, alpha Subunit; Methotrexate; Rats; Receptors, Neurotransmitter; Taurine; Vascular Endothelial Growth Factor A | 2015 |
Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis.
Topics: Alendronate; Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Calcium Phosphates; Cell Line; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Delivery Systems; Durapatite; Female; Humans; Methotrexate; Mice; Nanoparticles; Photoelectron Spectroscopy; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2017 |
Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo.
Topics: Alendronate; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone and Bones; Bone Resorption; Collagen; Cytokines; Drug Therapy, Combination; Female; Inflammation; Male; Methotrexate; Mice; Mice, Inbred C57BL; Muramidase; Osteoclasts; Osteogenesis; Rats; Rats, Wistar | 2018 |
Preparation, characterization and in vitro antitumor activity evaluation of hyaluronic acid-alendronate-methotrexate nanoparticles.
Topics: A549 Cells; Alendronate; Antimetabolites, Antineoplastic; Cell Proliferation; Endocytosis; Human Umbilical Vein Endothelial Cells; Humans; Hyaluronic Acid; Methotrexate; Nanoparticles | 2021 |